Abivax (ABVX) Stock Analysis: Guggenheim Maintains Bullish Stance Following Cancer Data Release

Key Takeaways

• Guggenheim maintained its Buy recommendation on Abivax (NASDAQ:ABVX) with a $175 price objective following analysis of 44-week maintenance trial data for obefazimod.
• Shares currently trade at $96.15, representing a remarkable 1,157% gain over the past twelve months, though sitting 35% beneath the 52-week peak of $148.83.
• Safety analysis revealed two non-melanoma skin cancer incidents and four melanoma cases, both falling within management’s previously communicated projections.
• Patients experiencing relapse during maintenance therapy successfully regained clinical and endoscopic remission following retreatment with the 50 mg dosage.
• The investment firm anticipates near-term trading in the $130-$150 range and designated Abivax as a Best Idea selection.

Shares of Abivax (NASDAQ:ABVX) are currently positioned at $96.15 following Guggenheim’s reaffirmation of its Buy recommendation and $175 price objective on Wednesday. The analysis comes on the heels of updated 44-week maintenance phase data from the biotechnology company’s obefazimod program targeting ulcerative colitis treatment.

Abivax S.A., ABVX

The biotech stock has experienced extraordinary movement throughout the previous year, surging more than 1,157%. However, it continues trading 35% under its 52-week peak of $148.83, highlighting the significant price swings that have characterized this equity.

Guggenheim’s analysis concentrated on safety information from the trial’s Part Two segment, a critical area receiving heightened investor attention. The investment firm noted that outcomes aligned with parameters previously established by company management.

Trial Safety Profile Analysis

The study documented two non-melanoma skin cancer incidents, both occurring in participants receiving the 50 mg dosage. This translates to an incidence rate of 0.48 per 100 patient years of exposure.

Abivax maintained the incidents were not attributable to the investigational therapy. Management noted pre-existing risk factors present in the affected participants as the likely cause.

This incidence rate remained within management’s previously communicated guidance band of 0.30 to 0.70. This consistency is significant for market participants evaluating whether the compound’s safety characteristics remain stable.

Additionally, four melanoma skin cancer cases were documented. These incidents were distributed equally between the 25 mg and 50 mg dosage cohorts.

The melanoma incidence rate registered at 0.95 per 100 patient years. This figure stays within the 0.70 to 1.40 range that management had previously communicated to investors.

Treatment Effectiveness and Wall Street Perspectives

Regarding therapeutic effectiveness, the findings appeared more promising. Participants who failed to achieve response during the induction period demonstrated continued improvement with extended obefazimod exposure beyond the initial eight-week period.

Participants experiencing relapse during the maintenance treatment phase successfully recaptured their clinical and endoscopic improvements. This recovery occurred following retreatment with the 50 mg dose by the 44-week assessment point.

Guggenheim characterized the data as sufficiently supportive to retain Abivax on its Best Idea roster. The firm projects shares will trade in the $130 to $150 band in coming months, representing a substantial premium to present valuations.

InvestingPro’s evaluation suggests the stock carries slight undervaluation at present price levels. The platform provides 11 supplementary ProTips for members examining Abivax’s financial condition and competitive positioning.

Multiple other analysts have recently weighed in on Abivax. Wolfe Research reduced its price objective to $136, referencing safety considerations requiring additional evaluation.

Truist Securities similarly modified its target to $135 while preserving a Buy recommendation. The firm also highlighted malignancy considerations as justification for measured optimism.

BTIG moved in the opposite direction, elevating its price target to $175. That upgrade followed the firm’s assessment of encouraging safety data from the ABTECT Maintenance Part 2 trial.

Previous results from the identical Phase 3 study demonstrated 37.2% of participants achieving clinical remission at Week 44 while receiving continued 50 mg therapy. Endoscopic remission was documented in 34.5% of participants in that earlier data release.

The post Abivax (ABVX) Stock Analysis: Guggenheim Maintains Bullish Stance Following Cancer Data Release appeared first on Blockonomi.